News Channels

12 May 2022 Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
11 May 2022 Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers
11 May 2022 Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase 1/2 Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans
11 May 2022 FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
11 May 2022 Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
11 May 2022 Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results
11 May 2022 Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
10 May 2022 Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
10 May 2022 Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial
10 May 2022 Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
10 May 2022 Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi
10 May 2022 Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors
10 May 2022 Pfizer to Acquire Biohaven Pharmaceuticals
10 May 2022 Eisai completes rolling submission to the U.S. FDA for biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway
10 May 2022 UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
09 May 2022 Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
09 May 2022 Ichnos Sciences announces selection of trispecific antibody ISB 2001 as next clinical candidate for relapsed/refractory multiple myeloma
09 May 2022 Elpiscience Announces FDA IND Clearance of ES014, a First-in-Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid Tumors
09 May 2022 Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors
09 May 2022 Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up